ALDH1A2 Protein
Overview
ALDH1A2 (Aldehyde Dehydrogenase 1 Family Member A2) is a cytosolic enzyme belonging to the aldehyde dehydrogenase superfamily, which catalyzes the oxidation of aldehydes to their corresponding carboxylic acids. The ALDH1A2 protein is encoded by the ALDH1A2 gene located on chromosome 15q21.3 in humans. As a member of the NAD+-dependent dehydrogenase family, ALDH1A2 plays critical roles in cellular detoxification and metabolic homeostasis. The enzyme is particularly notable for its retinoid metabolism function, catalyzing the conversion of retinaldehyde to retinoic acid, an essential signaling molecule for neuronal development and maintenance. ALDH1A2 is expressed across multiple tissues including the brain, liver, and kidneys, with significant localization in neurons and glial cells where its activity is essential for sustained neural function.
Function and Biology
ALDH1A2 functions as a NAD+-dependent oxidoreductase with multiple substrates and cellular roles. Its primary enzymatic function involves the conversion of various aldehyde substrates to their corresponding acids, a reaction critical for metabolic detoxification and removal of reactive aldehydes that accumulate during oxidative stress. The enzyme exhibits broad substrate specificity, processing endogenous aldehydes derived from lipid peroxidation, amino acid catabolism, and polyamine metabolism, as well as exogenous aldehydes from environmental exposure.
...ALDH1A2 Protein
Overview
ALDH1A2 (Aldehyde Dehydrogenase 1 Family Member A2) is a cytosolic enzyme belonging to the aldehyde dehydrogenase superfamily, which catalyzes the oxidation of aldehydes to their corresponding carboxylic acids. The ALDH1A2 protein is encoded by the ALDH1A2 gene located on chromosome 15q21.3 in humans. As a member of the NAD+-dependent dehydrogenase family, ALDH1A2 plays critical roles in cellular detoxification and metabolic homeostasis. The enzyme is particularly notable for its retinoid metabolism function, catalyzing the conversion of retinaldehyde to retinoic acid, an essential signaling molecule for neuronal development and maintenance. ALDH1A2 is expressed across multiple tissues including the brain, liver, and kidneys, with significant localization in neurons and glial cells where its activity is essential for sustained neural function.
Function and Biology
ALDH1A2 functions as a NAD+-dependent oxidoreductase with multiple substrates and cellular roles. Its primary enzymatic function involves the conversion of various aldehyde substrates to their corresponding acids, a reaction critical for metabolic detoxification and removal of reactive aldehydes that accumulate during oxidative stress. The enzyme exhibits broad substrate specificity, processing endogenous aldehydes derived from lipid peroxidation, amino acid catabolism, and polyamine metabolism, as well as exogenous aldehydes from environmental exposure.
A particularly important function of ALDH1A2 is its role in retinoid metabolism. The enzyme catalyzes the irreversible oxidation of retinaldehyde to all-trans retinoic acid (atRA), the active metabolite of vitamin A. Retinoic acid functions as a ligand for nuclear receptors (retinoic acid receptors, or RARs, and retinoid X receptors, or RXRs) that regulate gene transcription involved in neuronal differentiation, synaptic plasticity, and neuroinflammation control. This retinoic acid signaling pathway is essential for maintaining normal neuronal homeostasis and proper glial function throughout the lifespan.
ALDH1A2 expression is regulated by transcriptional factors responsive to oxidative stress and metabolic demands. The enzyme localizes primarily to the cytosol but exhibits dynamic subcellular redistribution under stress conditions, including translocation to mitochondria where it may engage with mitochondrial membranes during heightened oxidative challenge.
Role in Neurodegeneration
ALDH1A2 dysfunction has been implicated in multiple neurodegenerative diseases through several interconnected mechanisms. In Alzheimer's disease, reduced ALDH1A2 activity and expression have been observed in postmortem brain tissue from affected individuals, correlating with impaired retinoic acid signaling and compromised neuroinflammatory control. The loss of ALDH1A2 activity diminishes retinoic acid production, reducing the capacity of neurons and microglia to maintain appropriate inflammatory responses and cellular plasticity.
In Parkinson's disease and other α-synucleinopathies, impaired aldehyde detoxification by ALDH1A2 may contribute to accumulation of toxic aldehyde species that promote protein aggregation and neuronal death. Particularly relevant are aldehydes derived from dopamine metabolism, including 3,4-dihydroxyphenylacetaldehyde (DOPAL), which can form toxic protein adducts.
ALDH1A2 insufficiency also compromises the brain's capacity to manage lipid peroxidation byproducts, particularly 4-hydroxynonenal (4-HNE), which accumulates under oxidative stress and forms protein adducts that impair synaptic function and trigger neuroinflammation.
Molecular Mechanisms
The neuroprotective functions of ALDH1A2 operate through multiple molecular mechanisms. By maintaining efficient aldehyde catabolism, ALDH1A2 prevents accumulation of reactive aldehydes that would otherwise form protein crosslinks, impair proteasomal function, and activate inflammasome pathways. The enzyme's production of retinoic acid sustains signaling through RARs and RXRs, which regulate expression of antioxidant enzymes, neuroprotective growth factors, and genes controlling microglial activation state.
ALDH1A2 activity also influences NAD+ metabolism and mitochondrial function, as NAD+ regeneration by the enzyme supports sirtuins and poly-ADP-ribose polymerases (PARPs) involved in stress response and genomic stability.
Clinical and Research Significance
ALDH1A2 represents a therapeutic target for neurodegenerative disease intervention. Enhancing ALDH1A2 activity or expression could reduce toxic aldehyde burden and enhance neuroprotective retinoic acid signaling. Genetic variations in ALDH1A2 may contribute to individual susceptibility to neurodegeneration, making the enzyme relevant for precision medicine approaches. Current research explores ALDH1A2 as a biomarker for disease progression and therapeutic outcome assessment.
AlphaFold Structure
AlphaFold DB provides a predicted structure for ALDH1A2 / UniProt O94788 (model version 6): https://alphafold.ebi.ac.uk/entry/O94788.
AlphaFold reports a mean pLDDT confidence score of 95.75, indicating very high average confidence.
InterPro annotations highlight Aldehyde dehydrogenase domain domain (46-509); Aldehyde dehydrogenase, cysteine active site conserved site (313-324); Aldehyde/histidinol dehydrogenase homologous superfamily (28-513).
PDB coordinates: https://alphafold.ebi.ac.uk/files/AF-O94788-F1-model_v6.pdb mmCIF coordinates: https://alphafold.ebi.ac.uk/files/AF-O94788-F1-model_v6.cif.
Use the prediction as structural context for target assessment; local low-pLDDT segments may reflect disorder, flexible linkers, or unresolved domain orientation rather than a stable fold.